Evaluation of Multiple Myeloma Patients Presenting with Renal Failure in a University Hospital in the Year 2010

Creative Commons License

Suyani E., Sucak G. T., ERTEN Y., Cakar M. K., Ulusal G., Yagci M., ...More

RENAL FAILURE, vol.34, no.2, pp.257-262, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 34 Issue: 2
  • Publication Date: 2012
  • Doi Number: 10.3109/0886022x.2011.647205
  • Journal Name: RENAL FAILURE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.257-262
  • Keywords: multiple myeloma, renal failure, treatment, prognosis, STEM-CELL TRANSPLANTATION, STAGING SYSTEM, IMPACT, REVERSIBILITY, BORTEZOMIB, IMPAIRMENT
  • Gazi University Affiliated: Yes


Background: The aim of this cross-sectional study was to evaluate multiple myeloma patients presenting with renal failure in a University hospital. Methods: The records of all the patients diagnosed with multiple myeloma in the departments of hematology and nephrology at Gazi University Hospital between January 2010 and January 2011 were reviewed retrospectively. Renal failure was defined as a serum creatinine level of >= 2 mg/dL. Median age was 63 (range 37-80) years, with 13 male and 17 female patients. Results: Eight (26.7%) of the 30 patients had renal failure and 4 (50%) patients with renal failure required renal replacement therapy with hemodialysis after admission. Renal functions recovered in four (50%) of the eight patients after treatment. In one of the eight patients (12.5%) creatinine levels improved, but did not reach the level defined as reversal of renal failure. The renal functions of the three (37.5%) patients did not improve and they remained on chronic hemodialysis program during which one of them died due to a cerebrovascular accident and one other patient was lost due to follow-up. Conclusion: A substantial proportion of myeloma patients referred with renal failure might enjoy a disease-free survival and could be saved from chronic renal replacement therapy with prompt diagnosis and treatment in the era of new-generation anti-myeloma agents which provide fast and effective responses. Multiple myeloma should be considered in the differential diagnosis of acute renal failure even in the absence of hyperglobulinemia and hypercalcemia.